Middle East and Africa Transparent Plastic Market Outlook, 2030

The global menopause market has shifted from being overlooked to a major women’s health focus, driven by aging populations and growing awareness worldwide. The average onset age ranges from 45 to 55 years globally. Women spend more than 30% of their lives in postmenopause due to increased life expectancy. Around 75% of women experience vasomotor symptoms such as hot flashes and night sweats. The prevalence of menopausal women aged 45 to 55 is significant across all continents, with billions projected to enter menopause in the next decades. Awareness gaps exist globally. Less than 50% of healthcare providers receive formal menopause training. Many women in Southern Europe and rural India, about 60 to 70%, cannot connect menopause to long-term health risks such as osteoporosis and heart disease. Common symptoms worldwide include hot flashes, joint pain, vaginal dryness, and psychological distress. Hot flashes disrupt work for approximately 40% of women. Psychological distress affects job retention in about 10% of cases. Vaginal symptoms are often underreported in conservative cultures due to stigma. Gynecologists and endocrinologists handle complex cases in high-resource areas, while general practitioners provide frontline care globally, but fewer than 30% follow current guidelines. EMAS guidelines endorse hormone therapy for osteoporosis prevention, and WHO prioritizes digital health tools especially in low-resource settings. Dietary and genetic factors influence symptom severity. Mediterranean diets reduce symptoms by 30% compared to high-fat Western diets. Asian women tend to report fewer vasomotor symptoms but more joint pain. NGOs like the Menopause Foundation of Canada promote workplace policies, and South African radio campaigns help reduce stigma in multiple communities. Digital platforms like UAE’s MenoCare and Indonesia’s Halodoc help improve symptom tracking and access to care.

According to the research report ""Global Menopause Market Overview, 2030,"" published by Bonafide Research, the global Menopause market was valued at more than USD 17.45 Billion in 2024. Worldwide treatment preferences vary with growing interest in plant-based and natural remedies. Phytoestrogen-rich supplements such as soy and black cohosh dominate markets in Asia and South America. Herbal hybrids like Egypt’s MenoHerb and maca root from the Andes grow rapidly in traditional medicine sectors. Regulatory bodies like the FDA and EMA fast-track approval of novel therapies, including Bayer’s elinzanetant, a neurokinin antagonist approved in 2024. Regulatory oversight varies with India’s CDSCO having minimal controls on supplements, while Saudi Arabia’s SFDA mandates strict labeling. Telehealth expands care with platforms like China’s Ping An Good Doctor hosting 70% of menopause consultations, and Nigeria’s Mediverse cutting diagnosis delays by half. E-pharmacies contribute 35% of over-the-counter sales in the UK but less than 12% in rural Laos. Leading companies include Bayer with elinzanetant, Astellas Pharma with the first FDA-approved NK3 drug Veozah, Cadila in India producing MenoHerb, and Theramex offering treatments like Yselty for related conditions. Over 15 neurokinin antagonists are in late-stage trials, mainly in Europe and Japan. Startups use artificial intelligence to personalize menopause care regimens. Public health initiatives follow WHO’s Healthy Ageing framework in more than 20 countries. Insurance coverage varies widely with Germany reimbursing 90% of hormone therapy costs but Poland only 30%. Supplements are rarely covered by insurance anywhere.

Market Drivers

• Rising Aging Female Population: The global increase in life expectancy leads to a growing number of women entering menopause each year. This demographic shift creates higher demand for effective symptom management and treatment options. Healthcare systems and pharmaceutical companies respond by investing more in menopause-related therapies, boosting market growth worldwide.
• Growing Awareness and Education: Awareness campaigns by NGOs and medical societies have improved knowledge about menopause symptoms and health risks among women and healthcare providers. Digital health tools and social platforms also help reduce stigma and encourage more women to seek care, driving adoption of menopause treatments globally.

Market Challenges

• Limited Healthcare Provider Training: Many medical professionals receive inadequate education about menopause, resulting in underdiagnosis and inconsistent care. This issue is especially severe in rural and low-resource areas, where specialized care is scarce. Such gaps reduce treatment uptake and hinder the market's expansion.
• Cultural Stigma and Symptom Underreporting: In numerous regions, menopause remains a taboo topic, causing women to underreport symptoms like vaginal dryness or mood changes. Social and cultural barriers limit open discussion and delay treatment, negatively impacting women’s quality of life and limiting market potential.

Market Trends

• Digital Health and Telemedicine Growth: The use of AI-powered symptom tracking apps and teleconsultations expands access to menopause care, especially in remote or conservative areas. Digital platforms enable personalized management and improve patient engagement, transforming menopause treatment approaches worldwide.
• Preference for Plant-Based and Natural Remedies: Consumers increasingly favor phytoestrogen supplements such as soy and black cohosh over hormone therapy due to safety concerns. This shift drives growth in natural and herbal menopause products, reflecting a broader global trend towards holistic health and wellness.

Dietary supplements are the largest and fastest-growing treatment in the global menopause market because they provide a natural and easily accessible alternative to traditional hormone therapies, meeting the increasing demand for safer and holistic health solutions among menopausal women worldwide.

Dietary supplements have gained widespread acceptance because many women prefer natural products to manage their menopausal symptoms due to concerns about the side effects and risks associated with hormone replacement therapy. Ingredients like phytoestrogens found in soy, black cohosh, and red clover mimic estrogen’s effects in the body, helping to reduce hot flashes, night sweats, and mood swings without the need for prescription drugs. These supplements are often available over the counter, making them easy to purchase without medical consultations or prescriptions, which is particularly appealing in regions where healthcare access is limited or costly. The global trend toward wellness, organic products, and plant-based diets also supports the preference for dietary supplements, as consumers seek treatments that align with their lifestyle and health philosophies. Manufacturers benefit from fewer regulatory hurdles compared to pharmaceuticals, enabling quicker product launches and a wider variety of formulations, which attract a diverse consumer base. Marketing campaigns further educate women about the benefits of these supplements, increasing awareness and trust. The rising number of women entering menopause worldwide creates a growing customer base, driving market expansion. Additionally, dietary supplements are often perceived as safer and less invasive, encouraging long-term use and adherence. This natural appeal, accessibility, regulatory ease, and growing consumer demand explains why dietary supplements have become the dominant and fastest-growing treatment option in the global menopause market.

Menopause is the largest and fastest-growing stage in the global menopause market is due to the increasing number of women reaching the menopausal age worldwide, combined with heightened awareness and diagnosis of menopause-related symptoms that drive demand for targeted treatments during this critical phase.

Menopause marks a significant biological transition for women, generally occurring between ages 45 and 55, characterized by the permanent end of menstruation and a sharp decline in estrogen levels. This stage is associated with a range of symptoms including hot flashes, night sweats, mood changes, and increased risks of osteoporosis and cardiovascular disease. As life expectancy rises globally, women spend a longer portion of their lives in this stage, making effective management of menopausal symptoms a public health priority. Advances in healthcare and growing recognition of women’s health issues have led to better diagnosis and treatment, fueling market growth. More women now seek medical care to address symptoms that previously went unreported or untreated, increasing demand for hormone replacement therapies, non-hormonal treatments, and dietary supplements tailored specifically for menopause. Healthcare providers are also more equipped with guidelines and tools to support women during this phase, improving access to care. The rising prevalence of chronic conditions related to menopause drives a need for continuous medical support, further expanding the market. Additionally, societal shifts towards open discussion about menopause reduce stigma, encouraging women to pursue therapy and symptom relief. This combination of demographic growth, increased awareness, better healthcare infrastructure, and cultural changes contributes to menopause becoming the largest and fastest-growing stage in the global menopause market, with women actively seeking effective solutions to improve quality of life during this important phase.

Transdermal administration is the fastest-growing route in the global menopause market because it offers steady hormone delivery with fewer side effects compared to oral therapies.

Transdermal systems such as patches, gels, and sprays have become increasingly popular worldwide due to their ability to provide consistent hormone levels directly through the skin, bypassing the digestive system. This method avoids the first-pass metabolism in the liver, which reduces the risk of blood clots and cardiovascular issues often linked to oral hormone replacement therapy. Many studies have shown that transdermal estrogen carries a lower risk of stroke and heart problems, making it a safer option for many women. The ease of use also plays a critical role transdermal patches can be applied once or twice a week, and gels or sprays allow flexible dosing, which appeals to women seeking convenience and control over their symptoms. Additionally, transdermal delivery offers a non-invasive, painless alternative to injections or daily pills, increasing patient adherence to therapy. Healthcare providers globally are shifting towards recommending transdermal options as first-line treatments, supported by clinical guidelines from societies like the North American Menopause Society and European Menopause and Andropause Society. The rising focus on personalized medicine also boosts transdermal usage, as it allows customization of hormone doses based on individual needs. Moreover, insurance coverage for transdermal products has improved in many regions, reducing out-of-pocket expenses and further driving market growth. Digital health platforms and telemedicine have enhanced patient awareness and accessibility to transdermal therapies, especially in remote or underserved areas.

Hospitals remain the largest end users in the global menopause market because they provide comprehensive care combining diagnosis, treatment, and ongoing management under one roof.

These facilities bring together a range of specialists such as gynecologists, endocrinologists, and primary care physicians who collaborate to address the complex and varied symptoms associated with menopause. Hospitals are equipped with advanced diagnostic tools, including hormone level testing and bone density scans, which are essential for creating personalized treatment plans. Women with severe or multiple menopausal symptoms often prefer hospitals due to the availability of multidisciplinary care and immediate access to specialized treatments like hormone replacement therapy or management of related conditions such as osteoporosis and cardiovascular disease. The infrastructure of hospitals supports inpatient and outpatient care, allowing continuous monitoring and follow-up that improves treatment outcomes. Additionally, hospitals participate in clinical research and trials, which helps them stay at the forefront of new therapies and innovations, attracting patients who seek cutting-edge care. Insurance policies in many countries typically cover hospital services more comprehensively than other healthcare settings, reducing financial barriers for patients. Public health programs and awareness campaigns also often operate through hospitals, increasing patient inflow and encouraging early diagnosis and treatment. The trust placed in hospitals by patients, combined with their capacity to handle complex cases and provide a wide range of services, makes them the primary point of care for menopausal women globally.

Online pharmacies have rapidly become the fastest growing distribution channel in the global menopause market due to their convenience, accessibility, and ability to meet the evolving needs of menopausal women.

The rise of digital health technologies has made it easier for women to order menopause-related treatments such as hormone replacement therapies, dietary supplements, and non-hormonal options from the comfort of their homes. This eliminates the need to physically visit pharmacies or healthcare providers, which is particularly beneficial for those living in remote or underserved areas with limited access to traditional healthcare facilities. Online platforms operate 24/7, allowing patients to place orders at any time, with direct home delivery ensuring privacy and discretion, an important factor for many women who may feel uncomfortable seeking menopause products in person. The integration of telemedicine services with online pharmacies further streamlines care by enabling remote consultations, prescription renewals, and personalized advice, reducing barriers to treatment adherence. Subscription models and automatic refill options help ensure consistent use of therapies, which is crucial for managing menopausal symptoms effectively. Additionally, online pharmacies often provide detailed product information, customer reviews, and tailored recommendations, empowering women to make informed choices about their care. The COVID-19 pandemic accelerated the shift toward digital purchasing, making online pharmacies a preferred channel even after restrictions eased. Insurance compatibility and multiple digital payment options add to the ease of use, expanding access across socioeconomic groups.

North America leads the global menopause market mainly due to its well-established healthcare infrastructure combined with high awareness and adoption of advanced menopause therapies.

The dominance of North America in the menopause market stems from a combination of several interlinked factors that create a supportive environment for both patients and healthcare providers. The region benefits from a robust healthcare system where public and private sectors collaborate to provide widespread access to menopausal care, including hormone replacement therapies and non-hormonal alternatives. Health insurance coverage in the United States and Canada often includes reimbursement for menopause treatments, reducing financial barriers that might otherwise limit access. Additionally, the high level of awareness about menopause among women and medical professionals drives demand for effective management of symptoms. Many healthcare providers in North America receive specialized training on menopause, which enhances diagnosis and treatment quality. This education extends beyond doctors to include nurses, pharmacists, and allied health workers, fostering a comprehensive care network. Technological advances also play a significant role in the region’s market leadership. Telehealth platforms have become increasingly popular, allowing women to consult specialists remotely and improving access to care, especially in underserved areas. Digital health tools, such as symptom tracking apps and personalized treatment plans based on data analytics, further support patient engagement and adherence to therapies. The cultural acceptance and openness regarding menopause also contribute significantly. Women in North America tend to be more proactive in seeking medical advice for menopause-related symptoms, partly due to fewer stigmas compared to other regions. Pharmaceutical innovation is another key factor, with many leading global companies headquartered or conducting extensive research in North America. They frequently introduce novel products, including non-hormonal treatments targeting specific symptoms, which increases options available to patients.

• In May 2024, Noema Pharma initiated dosing in a Phase IIa study (NOE-PPM-201) of NOE-115, a groundbreaking investigational therapy targeting vasomotor symptoms and other menopause-related conditions. This open-label trial will assess the safety and efficacy of NOE-115, a monoamine modulator, in 30 women with moderate to severe vasomotor symptoms. Conducted at six US centers, the study aims to explore its potential in alleviating both VMS and additional menopausal symptoms.
• In May 2023, Astellas Pharma Inc. obtained approval from the FDA for VEOZAH, a groundbreaking nonhormonal neurokinin 3 (NK3) receptor antagonist. This marks the first-of-its-kind approval for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.
• In March 2023, Amyris, Inc. acquired MenoLabs, LLC, a company specializing in menopause treatment and research in this field. This strategic acquisition is poised to facilitate the expansion of Amyris, Inc.'s product portfolio in the realm of menopause treatments.
• In March 2022, Aptorum Group Limited, announced the highly anticipated commercial introduction of NativusWell®. This new dietary supplement is designed to support women's health during the various stages of menopause and is specifically targeted for the Chinese market.


***Please Note: It will take 48 hours (2 Business days) for delivery of the report upon order confirmation. Show more